Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding.

ABSTRACT: Two thirds of patients with heart failure and preserved ejection fraction (HFpEF) have an indication for oral anticoagulation (OAC) to prevent thromboembolic events. However, evidence regarding the safety of OAC in HFpEF is limited. Therefore, our aim was to describe bleeding events and to find predictors of bleeding in a large HFpEF cohort. We recorded bleeding events in a prospective HFpEF cohort. Out of 328 patients (median age 71 years (interquartile range (IQR) 67-77)), 64.6% (n = 212) were treated with OAC. Of those, 65.1% (n = 138) received vitamin-K-antagonists (VKA) and 34.9% (n = 72) non-vitamin K oral anticoagulants (NOACs). During a median follow-up time of 42 (IQR 17-63) months, a total of 54 bleeding events occurred. Patients on OAC experienced more bleeding events (n = 49 (2

SUBMITTER: Schrutka L 

PROVIDER: S-EPMC6724012 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature